Czech Republic
A limited medical framework took effect January 1, 2026, but the latest official availability statement said patient applications and waiting-list registration were not yet open.
International law · reviewed July 22, 2026
Psilocybin in Europe: different laws, narrow pathways
Europe has no single psilocybin access rule. Criminal law, possession, supply, medical access, and enforcement remain country-specific. European Union clinical-trial and medicines rules do not override each country’s controlled-substance laws or create public retail access.
Status in brief
What the current framework actually permits
Germany
Psilocybin remains a non-marketable narcotic. A named BfArM compassionate-use program for treatment-resistant depression is listed from June 18, 2026 through June 17, 2027.
Netherlands
Hallucinogenic mushroom fruiting bodies remain prohibited, while the Dutch Supreme Court says magic truffles or sclerotia fall outside the Opium Act. That is not a Europe-wide rule or medical approval.
Boundary
EU rules and domestic drug laws answer different questions
The EU Clinical Trials Regulation governs how medicinal-product trials are conducted. EMA workshops, recommendations, trials, and compassionate-use pathways do not by themselves create a marketing authorization, ordinary prescription access, personal-use legality, retail sales, or import rights across Europe.
Product-format context
Product descriptions, laboratory documentation, fulfillment policies, and client support remain on iMicrodosing.com. Deeper research remains on iMicrodosing.org.
Educational information only. Not medical advice. 21+ only.